Summary
| Direction in Long COVID | ↕ Inconsistent — reported as both higher and lower across studies, with no consistent direction |
|---|---|
| Category | Viral |
| Also described as | Viral RNAemia |
| Compared against | HC (healthy controls) |
| Associated symptoms | Viral reservoir hypothesis |
| Test type | Clinical or physiological test |
| Source | Baalbaki et al. 2025 — doi:10.1111/all.16526 |
| Condition atlas | Long COVID Biomarker Atlas |
Trials, interventions and tests
In clinical-trial registrations this marker maps to the outcome term To compare the SARS-CoV-2 RNA antigenemia (presence of viral components) in plasma with persistent COVID among the three treatment arms. (3 registered trials use a matching outcome measure).
Clinical trials using SARS-CoV-2 RNA as an outcome
- NCT07108036: A Study to Assess Anktiva in Patients With Long Covid-19. (Recruiting)
Outcome measure: Proportion of participants with reduced SARS-CoV-2 RNA in stool approximately 30 days post NAI administration. - NCT06766825: Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC) (Recruiting)
Outcome measure: To compare the SARS-CoV-2 RNA antigenemia (presence of viral components) in plasma with persistent COVID among the three treatment arms. - NCT05445674: Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study (Completed)
Outcome measure: Determination of residual SARS-CoV-2 particles (RNA) in plasma from subjects with PCC
Related Viral markers in Long COVID
Full list: Long COVID Biomarker Atlas.
Frequently asked questions
Is SARS-CoV-2 RNA high or low in Long COVID?
Mixed. Some studies report higher and others lower SARS-CoV-2 RNA in Long COVID compared with healthy controls, so no single direction is established. Source: Baalbaki et al. 2025.
What symptoms is SARS-CoV-2 RNA associated with in Long COVID?
The cited literature associates this marker with Viral reservoir hypothesis. These are population-level associations and do not mean the marker causes the symptoms.
Which test measures SARS-CoV-2 RNA?
It is measured as a clinical or physiological test. Many of the cited studies used research-grade assays, so clinical availability may vary.
Is one abnormal SARS-CoV-2 RNA result diagnostic of Long COVID?
No. No single biomarker is diagnostic of Long COVID. SARS-CoV-2 RNA findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.
Cite this page
Subscribe on Substack
Last reviewed: 2026-06-29 · Page generated from long-covid.json · Browse: Long COVID atlas · Biomarker Index · All marker pages
Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.